ibritumomab tiuxetan

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
ibritumomab tiuxetan

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®

ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))

Compound class: Antibody

Comment: A monoclonal antibody used as a radioimmunotherapy treatment.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. (1999) Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol, 15 (5): 1017-25. [PMID:10536187]

References

1. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. (1999)
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Int J Oncol, 15 (5): 1017-25. [PMID:10536187]